All In Biotech

Drug Trial Radar · NCT07451613

Safety and Tolerability Study of Human Neural Stem Cells for Huntington's Disease

Phase 1B/2A Study of the Safety and Tolerability of Human Neural Stem Cells for Huntington's Disease

Last checked: Nov 20, 2026Latest source record: Apr 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

21

Planned (sponsor's estimate)

Start

Apr 6, 2026

Primary completion

Jun 2028

Study completion Jan 2031

Sponsor

Lead sponsor
Leslie ThompsonAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
California Institute for Regenerative Medicine (CIRM); University of California, Irvine
First posted
Mar 5, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this research study is to determine whether an implantation of hNSC-01 is a safe and tolerable study intervention for Huntington's disease. This study is the first time that hNSC-01 is being tested in people.

Conditions

  • Huntington Disease

Interventions

  • hNSC-01Biological

    neural stem cell therapy

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with treatment-related adverse events as assessed by CTCAE v5.0 after 6 and 12 weeks after dosing.Time frame: Safety is assessed 6 weeks following each surgery for Cohort A and 12 weeks following cohort B-D completion

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University of California, Irvine

    Irvine, California · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.